|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this phase 2, multicentre, non-randomised, open-label study, we enrolled adult patients (aged ≥18 years) with pretreated metastatic stage IV BRAF(V600E)-mutant NSCLC who had documented tumour progression after at least one previous platinum-based chemotherapy and had had no more than three previous systemic anticancer therapies.
|
27283860 |
2016 |
|
rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Detection of T790M with plasma DNA was correlated with EGFR mutation type, exon 19 deletions and tumor progression.
|
26577492 |
2016 |
|
rs1284806277
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Stable S100P knockdown CRC cell lines were established to elucidate the relationship between S100P expression and tumor progression in vitro and in vivo.
|
26975699 |
2016 |
|
rs121913279
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The results suggest PIK3CA H1047R mutant cells have a selective advantage in breast, contribute to breast cancer susceptibility, and drive tumor progression during breast carcinogenesis, even when present as only a subpopulation of tumor cells.
|
27108388 |
2016 |
|
rs2057482
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, the rs2057482-CC genotype increases the susceptibility to PDAC and associated with cancer progression.
|
26872370 |
2016 |
|
rs557263543
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen.
|
26826182 |
2016 |
|
rs869320694
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen.
|
26826182 |
2016 |
|
rs961150162
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen.
|
26826182 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Many melanomas harbor a mutation in this pathway, BRAF(V600E), which constitutively activates MAPK signaling and expression of downstream target genes that facilitate tumor progression.
|
25989506 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is assumed that BRAF(V600E) may not confer growth advantage on paediatric PTCs, and many of these cases grow slowly, suggesting that additional factors may be important for tumour progression in paediatric PTCs.
|
26584635 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Beyond development, we can look into the effectiveness of already approved targeted therapies (eg, anti-BRAF(V600E) selective inhibitors, tyrosine kinase inhibitors, histone deacetylase inhibitors, inhibitors of DNA methylation, etc) to potentially test in ATC after learning the molecular mechanisms that aid in tumor progression.
|
25347569 |
2015 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Many melanomas harbor a mutation in this pathway, BRAF(V600E), which constitutively activates MAPK signaling and expression of downstream target genes that facilitate tumor progression.
|
25989506 |
2015 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is assumed that BRAF(V600E) may not confer growth advantage on paediatric PTCs, and many of these cases grow slowly, suggesting that additional factors may be important for tumour progression in paediatric PTCs.
|
26584635 |
2015 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Beyond development, we can look into the effectiveness of already approved targeted therapies (eg, anti-BRAF(V600E) selective inhibitors, tyrosine kinase inhibitors, histone deacetylase inhibitors, inhibitors of DNA methylation, etc) to potentially test in ATC after learning the molecular mechanisms that aid in tumor progression.
|
25347569 |
2015 |
|
rs351855
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Thus, our findings elucidate the molecular mechanism behind the genetic association of rs351855 with accelerated cancer progression and suggest that germline variants of cell-surface molecules that recruit STAT3 to the inner cell membrane are a significant risk for cancer prognosis and disease progression.
|
26675719 |
2015 |
|
rs11568818
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The -181A→G (rs11568818) polymorphism in the MMP7 promoter modulates gene expression and possibly affects cancer progression.
|
25847246 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Therefore, these data indicate that PRDX1 and PRDX6 expression not only may play a key role in papillary thyroid carcinogenesis via a BRAF V600E-dependent mechanism, but their determination could be considered as potential tumor marker for indicating tumor progression in PTCs, independently of BRAF status.
|
24316730 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Therefore, these data indicate that PRDX1 and PRDX6 expression not only may play a key role in papillary thyroid carcinogenesis via a BRAF V600E-dependent mechanism, but their determination could be considered as potential tumor marker for indicating tumor progression in PTCs, independently of BRAF status.
|
24316730 |
2014 |
|
rs121913529
|
|
|
0.050 |
GeneticVariation |
BEFREE |
To determine which KRAS effectors were responsible for tumor progression, we created four effector domain mutants (S35, G37, E38 and C40) in G12V-activated KRAS and expressed these alone or with BrafV600E in mouse lungs...
|
24489653 |
2014 |
|
rs3761548
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Stratified data also revealed an association of homozygous mutant genotype with advanced stage of tumor in premenopausal women (OR = 4.56; 95% CI = 1.07-19.38; p = 0.04) with disease duration of <6 months (OR = .10; 95% CI = 1.80-20.50; p = 0.002) suggestive of modulating effect of rs3761548 in tumor progression.
|
24338714 |
2014 |
|
rs104893626
|
|
|
0.010 |
GeneticVariation |
BEFREE |
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
|
24711662 |
2014 |
|
rs11549465
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Hypoxia-inducible factor-1 (HIF-1) influences cancer progression and metastasis through various mechanisms, and HIF-1α polymorphisms are reportedly associated with many cancers; however, the associations of HIF-1α P582S and A588T polymorphisms with the risk of digestive system cancer remain inconclusive.
|
24293391 |
2014 |
|
rs11549467
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Hypoxia-inducible factor-1 (HIF-1) influences cancer progression and metastasis through various mechanisms, and HIF-1α polymorphisms are reportedly associated with many cancers; however, the associations of HIF-1α P582S and A588T polymorphisms with the risk of digestive system cancer remain inconclusive.
|
24293391 |
2014 |
|
rs1273593548
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To determine which KRAS effectors were responsible for tumor progression, we created four effector domain mutants (S35, G37, E38 and C40) in G12V-activated KRAS and expressed these alone or with BrafV600E in mouse lungs...
|
24489653 |
2014 |
|
rs2016347
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In multivariable analysis, patients with primary invasive breast cancer carrying IGF1R_rs2016347 G allele had a significantly increased risk of early tumor progression (hazard ratio (HR) 2.01; adjusted P=0.004) and death (HR 1.84; adjusted P=0.023) compared with patients carrying G/T or T/T, independent of established clinicopathological determinants.
|
23459444 |
2014 |